Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press14310.17650/2313-805X-2018-5-2-16-23REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИIMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENTИММУНОТЕРАПИЯ НА ОСНОВЕ ДЕНДРИТНЫХ КЛЕТОК В ЛЕЧЕНИИ РАКА МОЧЕВОГО ПУЗЫРЯhttps://orcid.org/0000-0001-8925-440XIlnitskayaA. S.ИльницкаяА. С.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Алла Станиславовна Ильницкая.

115478 Москва, Каширское шоссе, 24

alla.ilnitskaya@inbox.ruhttps://orcid.org/0000-0003-4796-0386DanilovaA. B.ДаниловаА. Б.
Russian Federation

68 Leningradskaya St., Pesochniy Settlement, Saint Petersburg 197758

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

https://orcid.org/0000-0002-7472-4613BalduevaI. A.БалдуеваИ. А.
Russian Federation

68 Leningradskaya St., Pesochniy Settlement, Saint Petersburg 197758

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaНИИ канцерогенеза ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава РоссииN.N. Petrov National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России150520185216231807201818072018Copyright ©; 2018, Ilnitskaya A.S., Danilova A.B., Baldueva I.A.Copyright ©; 2018, Ильницкая А.С., Данилова А.Б., Балдуева И.А.2018Ilnitskaya A.S., Danilova A.B., Baldueva I.A.Ильницкая А.С., Данилова А.Б., Балдуева И.А.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/143

The development of an antitumor vaccine based on autologous dendritic cells (DCs) for bladder cancer treatment is extremely relevant today due to the proven high immunological potency of this type of tumor. Vaccination with DCs-based drugs as a monotherapy or in combination with other methods of treatment has shown to be effective in cancer therapy. The vaccine administration is considered to be safe, the associated side effects are insignificant and can be characterized as undesirable phenomena of 1st or 2nd degree. There are a number of issues that arise while creating DCs vaccines that need to be carefully resolved. Among them, the problem of selecting potential targets for the vaccine treatment, the ways to enhance the potency of the vaccine, and the selection of technology for obtaining a sufficient number of functional DCs should be specifically mentioned. The review focuses on the use of autoantigen or alloantibody material for the activation of DCs, and the results of experimental and clinical studies of DCs vaccines in bladder cancer.

bladder cancerimmunotherapydendritic-cell vaccineclinical trialsрак мочевого пузыряиммунотерапиядендритно-клеточная вакцинаклинические исследованияKamat A. M., Bağcıoğlu M., Huri E. What is new in non-muscle-invasive bladder cancer in 2016? Turkish J Urol 2017;43(1):9–13. DOI: 10.5152/tud.2017.60376. PMID: 28270945.Siegel R. L., Miller K. D., Jemal A. Cancer Statistics. CA Cancer J Clin 2017;67(1): 7–30. DOI: 10.3322/caac.21387. PMID: 28055103.Cookson M. S., Herr H. W., Zhang Z. F. et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158(1):62–7. DOI: 10.1097/00005392-199707000-00017. PMID: 9186324.Chua K. L., Kusumawidjaja G., Murgic J., Chua M. L. Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy? ESMO Open 2017;1(6):e000123. DOI: 10.1136/esmoopen-2016-000123. PMID: 28848661.Долгих Д. В., Широкорад В. И., Долгих В. Т. Лечение больных раком мочевого пузыря. Сибирский медицинский журнал 2016;(1):5–12.Шоуа А. Б. Иммунотерапия с использованием дендритных клеток в лечении рецидивного инвазивного переходноклеточного рака мочевого пузыря. Автореф. дис. … канд. мед. наук. М., 2009.Garg H., Suri P., Gupta J. C. et al. Survivin: a unique target for tumor therapy. Cancer Cell Int 2016;16:49. DOI: 10.1186/s12935-016-0326-1. PMID: 27340370.Donin N. M., Lenis A. T., Holden S. et al. Immunotherapy for the treatment of urothelial carcinoma. J Urol 2017;197(1):14–22. DOI: 10.1016/j.juro.2016.02.3005. PMID: 27460757.Donin N. M., Lenis A. T., Holden S. et al. Immunotherapy for the treatment of urothelial carcinoma. J Urol 2017;197(1):14–22. DOI: 10.1016/j.juro.2016.02.3005. PMID: 27460757.Redelman-Sidi G., Glickman M. S., Bochner B. H. The mechanism of action of BCG therapy for bladder cancer – a current perspective. Nat Rev Urol 2014;11(3):153–62. DOI: 10.1038/nrurol.2014.15. PMID: 24492433.Brausi M., Witjes J. A., Lamm D. et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international Bladder Cancer Group. J Urology 2011;186(6): 2158–67. DOI: 10.1016/j.juro.2011.07.076. PMID: 22014799.Muthigi A., George A. K., Brancato S. J., Agarwal P. K. Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. Ther Adv Urol 2016;8(3):203–14. DOI: 10.1177/1756287216628784. PMID: 27247630.Zabolotneva A. A., Zhavoronkov A., Garazha A. V. et al. Characteristic patterns of microRNA expression in human bladder cancer. Front Genet 2013;3:310. DOI: 10.3389/fgene.2012.00310. PMID: 23316212.Massari F., Di Nunno V., Cubelli M. et al. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat Rev 2018;64:11–20. DOI: 10.1016/j.ctrv.2017.12.007. PMID: 29407369.Massari F., Di Nunno V., Cubelli M. et al. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat Rev 2018;64:11–20. DOI: 10.1016/j.ctrv.2017.12.007. PMID: 29407369.Grüllich C. Immuntherapien ALS moderne tumor therapien. Radiologe 2017;57(10):822–5. DOI: 10.1007/s00117-017-0298-8. PMID: 28871357.Сальникова С. В., Славянская Т. А., Балдуева И. А. и др. Инновационные технологии в лечении рака мочевого пузыря. Аллергология и иммунология 2016;17(1):21–6.Славянская Т. А., Авдонкина Н. А., Сальникова С. В. Оптимизация условий получения жизнеспособной первичной культуры клеток уротелиальной карциномы. Аллергология и иммунология 2016;17(3):176–9.Славянская Т. А., Авдонкина Н. А. Современные подходы и достижения в лечении рака мочевого пузыря. Аллергология и иммунология 2016;17(1):50–1.Thompson D. B., Siref L. E., Feloney M. P. et al. Immunological basis in the pathogenesis and treatment of bladder cancer. Expert Rev Clin Immunol 2015;11(2):265–79. DOI: 10.1586/1744666X.2015.983082. PMID: 25391391.Constantino J., Gomes C., Falcao A. et al. Antitumor dendritic cell-based vaccines: lessons from 20-years of clinical trials and future perspectives. Transl Res 2016;168:74–95. DOI: 10.1016/j.trsl.2015.07.008. PMID: 26297944.Kitadani J., Ojima T., Iwamoto H. et al. Cancer vaccine therapy using carcinoembryonic antigen – expressing dendritic cells generated from induced pluripotent stem cells. Sci Rep 2018;8(1):4569. DOI: 10.1038/s41598-018-23120-z. PMID: 29545628.Kitadani J., Ojima T., Iwamoto H. et al. Cancer vaccine therapy using carcinoembryonic antigen – expressing dendritic cells generated from induced pluripotent stem cells. Sci Rep 2018;8(1):4569. DOI: 10.1038/s41598-018-23120-z. PMID: 29545628.Fernandez N. C., Lozier A., Flament C. et al. Dendritic cells directly trigger NK-cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5(4):405–11. DOI: 10.1038/7403. PMID: 10202929.Hanke N., Alizadeh D., Katsanis E., Larmonier N. Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Crit Rev Immunol 2013;33(1):1–21. PMID: 23510023.Bagaev A., Pichugin A., Nelson E. L. et al. Anticancer mechanisms in two murine bone marrow-derived dendritic cell subsets activated with tlr4 agonists. J Immunol 2018;200(7):2656–69. DOI: 10.4049/jimmunol.1701126. PMID: 29500244.Bagaev A., Pichugin A., Nelson E. L. et al. Anticancer mechanisms in two murine bone marrow-derived dendritic cell subsets activated with tlr4 agonists. J Immunol 2018;200(7):2656–69. DOI: 10.4049/jimmunol.1701126. PMID: 29500244.Sabado R. L., Balan S., Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res 2017;27(1):74–95. DOI: 10.1038/cr.2016.157. PMID: 28025976.Sharma P., Shen Y., Wen S. et al. Cancer-testis antigens: expression and correlation with survivalin human urothelial carcinoma. Clin Cancer Res 2006;12(18):5442–7. DOI: 10.1158/1078-0432.CCR-06-0527. PMID: 17000678.Sharma P., Shen Y., Wen S. et al. Cancer-testis antigens: expression and correlation with survivalin human urothelial carcinoma. Clin Cancer Res 2006;12(18):5442–7. DOI: 10.1158/1078-0432.CCR-06-0527. PMID: 17000678.Hirohashi Y., Torigoe T., Maeda A. et al. An HLA-A24-restricted cytotoxic T-lymphocyte epitope of a tumorassociated protein, survivin. Clin Cancer Res 2002;8(6):1731–9. PMID: 12060610.Ragai R. M., Robin D. H. Human cell culture protocols. 3rd edn. Methods in Molecular Biology. Humana Press, 2012. Pp. 31–43.Балдуева И. А., Славянская Т. А., Пипиа Н. П. и др. Особенности культивирования клеток уротелиальной карциномы, пригодных для создания персонифицированной дендритноклеточной вакцины против рака мочевого пузыря. II Российский онкологический форум с международным участием «Белые Ночи – 2016». Сборник тезисов, 2016. С. 228.Hwang E. C., Jung S. I., Lee H. J. et al. Generation of potent cytotoxic T lymphocytes against in male patients with non-muscle invasive bladder cancer by dendritic cells loaded with dying T24 bladder cancer cells. Int Braz J Urol 2017;43(4):615–27. DOI: 10.1590/S1677-5538.IBJU.2016.0274. PMID: 28266813.Palucka A. K., Ueno H., Connolly J. et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 2006;29(5):545–57. DOI: 10.1097/01.cji.0000211309. 90621.8b. PMID: 16971810.Koido S. Dendritic-tumor fusion cellbased cancer vaccines. Ed. T. Dittmar. Int J Mol Sci 2016;17(6):828. https://doi.org/10.3390/ijms17060828.Koido S. Dendritic-tumor fusion cellbased cancer vaccines. Ed. T. Dittmar. Int J Mol Sci 2016;17(6):828. https://doi.org/10.3390/ijms17060828.Troy A. J., Davidson P. J., Atkinson C. H., Hart D. N. CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated. J Urol 1999;161(6):1962–7. PMID: 10332481.Engleman E. G. Dendritic cell-based cancer immunotherapy. Semin Oncol 2003;30(3 Suppl 8):23–9. PMID: 12881809.Engleman E. G. Dendritic cell-based cancer immunotherapy. Semin Oncol 2003;30(3 Suppl 8):23–9. PMID: 12881809.Aarntzen E. H., de Vries I. J., Göertz J. H. et al. Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunol Immunother 2012;61(11):2003–11. DOI: 10.1007/s00262-012-1263-z. PMID: 22527252.Leonhartsberger N., Ramoner R., Putz T. et al. Antigen-independent immune responses after dendritic cell vaccination. Cancer Immunol Immunother 2007;56(6):897–903. DOI: 10.1007/s00262-006-0245-4. PMID: 17106716.Leonhartsberger N., Ramoner R., Putz T. et al. Antigen-independent immune responses after dendritic cell vaccination. Cancer Immunol Immunother 2007;56(6):897–903. DOI: 10.1007/s00262-006-0245-4. PMID: 17106716.Weide B., Pascolo S., Scheel B. et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009;32(5):498–507. DOI: 10.1097/CJI.0b013e3181a00068. PMID: 19609242.Pizarro-Bauerle J., Maldonado I., Sosoniuk-Roche E. et al. Molluskan hemocyanins activate the classical pathway of the human complement system through natural antibodies. Front Immunol 2017;8:188. DOI: 10.3389/fimmu.2017.00188. PMID: 28286504.Engell-Noerregaard L., Hansen T. H., Andersen M. H. et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009;58(1):1–14. DOI: 10.1007/s00262-008-0568-4. PMID: 18719915.Jakob T., Walker P. S., Krieg A. M. et al. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimula tory DNA. J Immunol 1998;161(6):3042–9. PMID: 9743369.Sparwasser T., Koch E. S., Vabulas R. M. et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998;28(6):2045–54. DOI: 10.1002/(SICI)1521–4141 (199806)28:06<2045:: AID–IMMU2045>3.0.CO;2–8. PMID: 9645386.Sparwasser T., Koch E. S., Vabulas R. M. et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998;28(6):2045–54. DOI: 10.1002/(SICI)1521–4141 (199806)28:06<2045:: AID–IMMU2045>3.0.CO;2–8. PMID: 9645386.Hegele A., Dalpke A., Heeg K. et al. Immunostimulatory CpG oligodeoxynucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model. Tumor Biol 2005;26(5):274–80.Arab S., Motamedi M., Khansari N. et al. Dendritic cell Maturation with CpG for tumor Immunotherapy. Iran J Immunol 2006;3(3):99–105. DOI: IJIv3i3A1. PMID: 18698118.Беседнова Н. Н., Федянина Л. Н. Противоопухолевое действие экзогенной дезоксирибонуклеиновой кислоты. Тихоокеанский медицинский журнал 2009;(3):12–8.Belisle J. T., Vissa V. D., Sievert T. et al. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997;276(5317):1420–2. PMID: 9162010.Huygen K., Content J., Denis O. et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996;2(8):893–8. PMID: 8705859.Borremans M., de Wit L., Volckaert G. et al. Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of Mycobacterium tuberculosis. Infect Immun 1989;57(10):3123–30. PMID: 2506131.Montgomery D. L., Huygen K., Yawman A. M. et al. Induction of humoral and cellular immune responses by vaccination with M. tuberculosis antigen 85 DNA. Cell Mol Biol (Noisy-le-Grand) 1997;43(3):285–92. PMID: 9193782.Nakano H., Nagata T., Suda T. et al. Immunization with dendritic cells retrovirally transduced with mycobacterial antigen 85A gene elicits the specific cellular immunity including cytotoxic T-lymphocyte activityspecific to an epitope on antigen 85A. Vaccine 2006;24:2110–9.Xie X. F., Ding Q., Hou J. G., Chen G. Inhibitory effects of a dendritic cell vaccine loaded with radiation-induced apoptotic tumor cells on tumor cell antigens in mouse bladder cancer. Genet Mol Res 2015;14(3):7548–55. DOI: 10.4238/2015.July.3.30. PMID: 26214433.Zhang P., Wang J., Wang D. et al. Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer. Int Immunopharmacol 2012;14(3):252–60. DOI: 10.1016/j.intimp.2012.07.014. PMID: 22884511.Tanaka T., Kitamura H., Inoue R. et al. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer – results from phase I clinical trials. Clin Dev Immunol 2013;2013:262967. DOI: 10.1155/2013/262967. PMID: 24363758.Kikkawa K., Fujii R., Kuramoto T. et al. Dendritic cells with transduced survivin gene induce specific cytotoxic T-lymphocytes in human urologic cancer cell lines. Urology 2009;74(1):222–8. DOI: 10.1016/j.urology.2008.12.045. PMID: 19285711.Kikkawa K., Fujii R., Kuramoto T. et al. Dendritic cells with transduced survivin gene induce specific cytotoxic T-lymphocytes in human urologic cancer cell lines. Urology 2009;74(1):222–8. DOI: 10.1016/j.urology.2008.12.045. PMID: 19285711.Li X. Z., Han Y., Tian J. et al. Enhancement of dendritic cells with melanoma-associated antigen 3 for inducing cytotoxicity by cytotoxic T-lymphocytes on bladder cancer BIU-87 cells. Genet Mol Res 2016;15(3). DOI: 10.4238/gmr.15039001. PMID: 27706668.Tanaka F., Fujie T., Tahara K. et al. Induction of antitumor cytotoxic T-lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997;57(20):4465–8. PMID: 9377553.Nishiyama T., Tachibana M., Horiguchi Y. et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyteantigen-A24specific MAGE-3 peptide. Clin Cancer Res 2001;7(1):23–31. PMID: 11205913.Nishiyama T., Tachibana M., Horiguchi Y. et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyteantigen-A24specific MAGE-3 peptide. Clin Cancer Res 2001;7(1):23–31. PMID: 11205913.Zhao J., Xu W., Zhang Z. et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol 2015;47(1):87–94. DOI: 10.1007/s11255-014-0866-z. PMID: 25384433.Bajorin F., Sharma P., Gomella G. et al. NeuACT, a phase II randomized, openlabel trial of DN24-02: updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer. J Clin Oncol 2014;32(4):296.Bajorin F., Sharma P., Gomella G. et al. NeuACT, a phase II randomized, openlabel trial of DN24-02: updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer. J Clin Oncol 2014;32(4):296.Clinical Trials.govidentifier: NCT01730118.Clinical Trials.gov identifier: NCT01730118. 1. Kamat A. M., Bağcıoğlu M., Huri E. What is new in non-muscle-invasive bladder cancer in 2016? Turkish J Urol 2017;43(1):9–13. DOI: 10.5152/tud.2017.60376. PMID: 28270945.